Selank Research: Tuftsin-Derived Biology, Animal Studies, and Human Evidence

The short version

Selank, also called TP-7, is a synthetic seven-amino-acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its first four residues reproduce tuftsin, a naturally occurring tetrapeptide associated with immune-cell biology, while the added Pro-Gly-Pro segment makes Selank a distinct molecule rather than another name for tuftsin.

The evidence is uneven. Biochemical and rodent studies report effects on peptide-degrading enzymes, neurotransmission-related gene expression, cytokines, behavior, and stress-related models. Human publications include small, regionally concentrated studies in anxiety-related disorders and a small functional-connectivity experiment in healthy volunteers. These findings support continued investigation, but they do not establish broad clinical efficacy, long-term safety, or cognitive enhancement.

Selank is not an FDA-approved drug. FDA currently lists selank acetate among bulk substances withdrawn from nomination after identifying concerns about aggregation, peptide-related impurities, possible immunogenicity for certain routes, and insufficient human safety information. A supplier listing or certificate of analysis does not resolve those clinical questions.

Identity: Selank is tuftsin-derived, not tuftsin itself

The sequence distinction is the first due-diligence checkpoint. Tuftsin is Thr-Lys-Pro-Arg; Selank extends that sequence with Pro-Gly-Pro. Publications may call Selank a tuftsin analogue, a tuftsin-derived peptide, TKPRPGP, or TP-7. Those labels point to the same seven-residue sequence only when the complete chemical identity is actually specified.

A paper about tuftsin, Pro-Gly-Pro, or another glyproline does not automatically establish a Selank effect. Terminal chemistry, salt or counterion form, peptide content, aggregation, degradation, and sample handling can also change what material was tested. Supplier documentation should therefore identify the complete sequence and material form rather than relying on the name alone.

Biochemical evidence: enzyme effects are mechanism clues

Early biochemical work tested Selank against enkephalin-degrading activity in human serum. The researchers reported dose-dependent inhibition of enzymes involved in enkephalin degradation. A related clinical-biological study measured leu-enkephalin half-life alongside symptom scales and reported changes during Selank exposure.

These observations are mechanistic leads, not proof of a therapeutic pathway. A change in enzyme activity in serum does not establish where the peptide acts in the body, which molecular target is necessary, how durable the effect is, or whether the change causes a meaningful clinical outcome. The evidence does not support reducing Selank to one settled mechanism.

Animal evidence: GABA-related expression and behavior

In rat frontal cortex, one study measured 84 neurotransmission-related genes after exposure to Selank or GABA. The investigators reported altered expression across genes involving receptors, transporters, and ion channels, with an early correlation between the Selank and GABA expression patterns. The authors proposed an association with GABAergic modulation, but gene-expression similarity is not the same as demonstrating direct binding to a specific GABA receptor site.

Other rodent studies have used stress, anxiety-like behavior, object recognition, ethanol exposure, or withdrawal models. A 2019 rat study reported effects on object recognition and brain-derived neurotrophic factor measurements in an ethanol-related model. Such experiments can reveal biological activity under controlled conditions, but the outcome depends on species, strain, injury or stress model, comparator, timing, and behavioral assay.

Animal behavior cannot be translated directly into a diagnosis or treatment effect in people. A result labeled anxiolytic, cognitive, or protective in a rodent model remains a model-specific finding until replicated and tested against clinically meaningful human outcomes.

• Biochemical result: a molecular interaction or enzyme endpoint under defined assay conditions
• Animal result: a behavioral, molecular, or tissue endpoint in a specific model
• Human result: an observation in people that must be judged by trial design and outcome quality
• Supplier result: an analytical claim about one sample or lot, not evidence of a biological benefit

Human anxiety studies: signals with important limits

A 2008 Russian-language publication described 62 people with generalized anxiety disorder or neurasthenia: 30 received Selank and 32 received medazepam. The abstract reports similar changes in anxiety ratings and additional antiasthenic or psychostimulant observations for Selank, while also discussing leu-enkephalin measurements.

A 2014 comparative study included 60 patients with phobic-anxiety, generalized-anxiety, or somatoform diagnoses and compared Selank with phenazepam. Its abstract reports anxiety and quality-of-life findings. However, the readily accessible record does not provide the full statistical and operational detail expected for confident modern appraisal, such as a prospectively registered protocol, complete allocation and blinding procedures, effect estimates with uncertainty, and comprehensive adverse-event reporting.

These are genuine human studies, but they are small, published in one regional clinical literature, and not supported by a large independent multicenter program. They do not establish effectiveness across anxiety disorders, comparative superiority, durability, or a general safety profile. They also do not justify extending patient findings to healthy cognition or everyday stress.

Human biomarker and imaging studies do not establish benefit

A separate publication in patients with anxiety-asthenic disorders reported changes in serum Th1/Th2 cytokine balance during Selank exposure and described ex-vivo effects in peripheral blood cells. Biomarker changes can support a biological hypothesis, but they are not equivalent to symptom improvement, reduced disease risk, or immune benefit.

A 2020 functional-connectivity study examined resting-state brain imaging in 52 healthy participants across Selank, Semax, and placebo groups. The authors reported group differences in connectivity involving predefined brain regions. A short-term fMRI signal is an imaging endpoint, not proof of improved attention, memory, mood, productivity, or long-term brain health.

Small samples, multiple network comparisons, short observation windows, and the absence of patient-centered outcomes sharply limit translation. Imaging and cytokine studies should therefore be described as mechanistic human evidence rather than efficacy trials.

What the evidence does not establish

The current literature does not establish broad efficacy for anxiety, depression, attention, memory, sleep, withdrawal, neuroprotection, or immune enhancement. It also does not provide a dependable long-term safety database across diverse populations or resolve interactions, reproductive effects, immune reactions, or risks from different formulations.

Claims that Selank is non-sedating, non-addictive, side-effect free, or safer than established medicines require direct and adequately powered comparative evidence. A small study, animal behavior, biochemical plausibility, or absence of a reported event cannot support those categorical claims.

• No basis for converting rat gene-expression changes into a human treatment claim
• No basis for treating cytokine shifts as proof of immune benefit
• No basis for treating a short-term fMRI difference as cognitive enhancement
• No basis for generalizing small regional studies to broad populations
• No basis for inferring long-term safety from limited or sparsely reported exposure

FDA status and registered-trial context

No FDA-approved Selank drug product was identified as of this review date. FDA's current compounding safety page lists selank acetate, also called TP-7, among nominated bulk substances that were withdrawn. The agency states that compounded products may pose immunogenicity risk for certain routes because of possible aggregation and peptide-related impurities and that important human safety information is lacking.

That FDA entry is not a finding that every sample is contaminated or that every experimental result is invalid. It is a regulatory safety and evidence statement about compounded drug products, and it reinforces why analytical characterization and human safety cannot be inferred from a name or headline purity number.

ClinicalTrials.gov searches can change and do not capture every historical or non-U.S. study. Registry presence would not equal approval, and absence would not prove that no human exposure ever occurred. Current status claims should name the database and review date.

Scientific evidence and supplier evidence answer different questions

A scientific paper asks what happened with a defined test article in a particular experiment. Supplier documentation asks whether a current sample or lot has the identity, purity, quantity, and other attributes represented. A positive paper cannot authenticate a commercial vial, and a coherent analytical report cannot prove an anxiety, cognitive, or immune effect.

The phrase research use only is an intended-use restriction, not an analytical result. Likewise, a supplier's reference to published Selank research does not show that its material matches the sequence, form, impurity profile, stability, or handling of the article's test material.

Analytical questions for Selank research material

For a seven-residue peptide, incomplete sequences, closely related tuftsin fragments, deletion products, oxidation, deamidation where chemically relevant, and aggregation can matter. Documentation should connect the offered lot to sequence-appropriate identity evidence, a stated chromatographic method, numerical results, test dates, and the laboratory that performed the work.

Mass spectrometry can support molecular identity when expected and observed species are reported coherently. HPLC area percentage describes detector response under one method; it does not by itself measure net peptide content or exclude every relevant impurity. Water, residual solvents, counterions, and other non-peptide mass can make total vial mass different from target-peptide content.

Sterility and endotoxin are separate attributes requiring separate methods when relevant to an experiment. Neither follows from a purity chromatogram, and no analytical panel establishes suitability for human or veterinary use.

• Does the report identify Thr-Lys-Pro-Arg-Pro-Gly-Pro and the terminal form?
• Is the tested lot the same lot currently offered?
• Are identity, chromatographic purity, and quantitative peptide content reported separately?
• Are expected and observed mass species, chromatographic conditions, dates, and laboratory identity visible?
• Are aggregation, degradation, water, counterion, sterility, and endotoxin claims made only when supported by suitable methods?

Unresolved research questions

The most important open questions are which molecular targets are necessary, whether reported gene-expression and behavioral findings replicate independently, whether any effect produces a clinically meaningful outcome, and what risks emerge with longer or broader exposure.

More informative human research would use prospective registration, adequate randomization and blinding, placebo and active comparators where appropriate, independently characterized test material, prespecified outcomes, transparent effect estimates, and complete adverse-event reporting. Independent replication outside the originating research network would materially strengthen confidence.

FAQ: Is Selank the same as tuftsin?

No. Selank contains the four-residue tuftsin sequence followed by Pro-Gly-Pro. That makes it tuftsin-derived, but it is a distinct seven-residue molecule. Evidence for tuftsin or another glyproline should not be transferred to Selank without direct support.

FAQ: Do GABA-related findings prove an anti-anxiety effect?

No. Rat gene-expression patterns and proposed GABAergic modulation are mechanistic evidence. They do not identify one established human receptor mechanism or prove clinical effectiveness. Human efficacy must be evaluated in adequately controlled trials with meaningful outcomes.

FAQ: Is Selank FDA approved?

No FDA-approved Selank drug product was identified as of October 19, 2026. FDA also states that important safety information for selank acetate is lacking and identifies potential concerns for certain compounded routes. Research labeling, foreign availability, or a supplier certificate does not create FDA approval.

The defensible conclusion

Selank has a clearly described tuftsin-derived sequence and a body of biochemical, animal, and limited human research. The literature supports the narrower conclusion that Selank can affect measured molecular, behavioral, biomarker, and imaging endpoints under specific study conditions.

It does not support broad claims of proven anxiety treatment, cognitive enhancement, immune benefit, or established long-term safety. Due diligence should keep four layers separate: exact chemical identity, preclinical biology, limited human evidence, and lot-specific supplier documentation.